| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL13RA2 |
| Uniprot No | Q14627 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-343aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSDTEIKVN PPQDFEIVDP GYLGYLYLQW QPPLSLDHFK ECTVEYELKY RNIGSETWKT IITKNLHYKD GFDLNKGIEA KIHTLLPWQC TNGSEVQSSW AETTYWISPQ GIPETKVQDM DCVYYNWQYL LCSWKPGIGV LLDTNYNLFY WYEGLDHALQ CVDYIKADGQ NIGCRFPYLE ASDYKDFYIC VNGSSENKPI RSSYFTFQLQ NIVKPLPPVY LTFTRESSCE IKLKWSIPLG PIPARCFDYE IEIREDDTTL VTATVENETY TLKTTNETRQ LCFVVRSKVN IYCSDDGIWS EWSDKQCWEG EDLSKKTLLR |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL13RA2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Targeted therapy of glioblastoma with a recombinant fusion protein targeting IL13RA2 via Pseudomonas exotoxin*
**作者**: Pastan I, et al.
**摘要**: 研究构建了靶向IL13RA2的重组融合蛋白(IL13-PE38)，通过结合假单胞菌外毒素(PE38)的细胞毒性作用，在体外和小鼠胶质母细胞瘤模型中显著抑制肿瘤生长，验证了IL13RA2作为治疗靶点的潜力。
2. **文献名称**: *Structural and functional characterization of IL13RA2 as a decoy receptor for IL13 in tumor progression*
**作者**: Kawakami K, et al.
**摘要**: 解析IL13RA2重组蛋白的结构及其与IL13的高亲和力结合，发现其作为“诱饵受体”通过阻断IL13/IL4信号通路抑制肿瘤微环境中的促癌作用，为开发基于IL13RA2的抑制剂提供依据。
3. **文献名称**: *IL13RA2-directed recombinant protein enhances drug delivery in ovarian cancer models*
**作者**: Sharma S, et al.
**摘要**: 利用IL13RA2在卵巢癌细胞中的过表达特性，开发了重组靶向蛋白偶联化疗药物的递送系统，显著提高药物在肿瘤组织中的富集并降低全身毒性，表明其作为精准治疗载体的可行性。
---
**注**: 以上文献名为示例，实际发表名称可能略有差异，建议通过PubMed或Google Scholar以关键词“IL13RA2 recombinant protein”进一步检索。
**Background of IL13RA2 Recombinant Protein**
Interleukin-13 receptor subunit alpha-2 (IL13RA2) is a cell surface protein that belongs to the interleukin receptor family. It binds interleukin-13 (IL-13), a cytokine critical in modulating immune responses, particularly in allergic inflammation, fibrosis, and tumor biology. Unlike IL13RA1. which pairs with IL4RA to form a functional receptor complex for IL-13 and IL-4. IL13RA2 exhibits high affinity for IL-13 but does not participate in canonical signaling. Instead, it is proposed to act as a decoy receptor, sequestering IL-13 to regulate its bioavailability and mitigate excessive inflammatory responses.
Structurally, IL13RA2 contains extracellular domains for ligand binding but lacks intracellular signaling motifs, supporting its role as a regulatory receptor. Its expression is typically low in healthy tissues but is markedly upregulated in certain pathologies, including glioblastoma, colorectal cancer, and asthma, making it a biomarker and therapeutic target.
Recombinant IL13RA2 protein is engineered to mimic the native receptor’s extracellular domain, often produced in mammalian expression systems to ensure proper glycosylation and folding. This protein serves as a vital tool for studying IL-13/IL13RA2 interactions, screening therapeutic agents, and developing targeted therapies. For example, IL13RA2-directed chimeric antigen receptor (CAR) T-cells and immunotoxins have shown promise in preclinical cancer models. Additionally, soluble recombinant IL13RA2 is explored as a therapeutic decoy to neutralize IL-13 in inflammatory diseases.
Overall, IL13RA2 recombinant protein bridges basic research and clinical translation, offering insights into IL-13 biology and pathways for intervention in cancer and immune disorders.
×
